AML patients who experienced multiple relapses or relapsed post-transplant had a higher percentage of PD-1-positive/CD8-positive T cells than that of newly diagnosed or first relapsed patients, and their TP-53-mutated leukemic cells more frequently expressed PD-L1. The gene discussed is CD8A; the disease is acute myeloid leukemia.